PERTUZUMAB

N/A

Manufactured by Genentech, Inc.

54,351 FDA adverse event reports analyzed

Last updated: 2026-04-14

About PERTUZUMAB

PERTUZUMAB is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Genentech, Inc.. The most commonly reported adverse reactions for PERTUZUMAB include DIARRHOEA, OFF LABEL USE, NAUSEA, FATIGUE, ALOPECIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PERTUZUMAB.

Top Adverse Reactions

DIARRHOEA3,643 reports
OFF LABEL USE2,279 reports
NAUSEA1,856 reports
FATIGUE1,840 reports
ALOPECIA1,537 reports
MYELOSUPPRESSION1,412 reports
DISEASE PROGRESSION1,290 reports
VOMITING1,229 reports
DYSPNOEA1,156 reports
NEUROPATHY PERIPHERAL1,091 reports
DEATH1,073 reports
PYREXIA1,036 reports
NEUTROPENIA970 reports
RASH897 reports
ANAEMIA844 reports
ASTHENIA795 reports
HEADACHE763 reports
FEBRILE NEUTROPENIA733 reports
EJECTION FRACTION DECREASED695 reports
DECREASED APPETITE671 reports
PAIN622 reports
METASTASES TO CENTRAL NERVOUS SYSTEM616 reports
PRURITUS597 reports
PNEUMONIA595 reports
NO ADVERSE EVENT587 reports
DRUG INEFFECTIVE563 reports
WEIGHT DECREASED540 reports
CONSTIPATION538 reports
CHILLS537 reports
THROMBOCYTOPENIA529 reports
MUCOSAL INFLAMMATION513 reports
ABDOMINAL PAIN503 reports
COUGH501 reports
MALAISE486 reports
BACK PAIN479 reports
PLATELET COUNT DECREASED466 reports
DIZZINESS461 reports
URINARY TRACT INFECTION459 reports
ARTHRALGIA446 reports
WHITE BLOOD CELL COUNT DECREASED442 reports
STOMATITIS438 reports
INFUSION RELATED REACTION423 reports
DEHYDRATION406 reports
EPISTAXIS400 reports
CARDIAC FAILURE398 reports
HAIR COLOUR CHANGES396 reports
HAIR TEXTURE ABNORMAL396 reports
MADAROSIS389 reports
POLYNEUROPATHY387 reports
HYPOKALAEMIA384 reports
PARAESTHESIA380 reports
MYALGIA376 reports
HYPOTENSION365 reports
PLEURAL EFFUSION360 reports
BREAST CANCER METASTATIC357 reports
INTERSTITIAL LUNG DISEASE343 reports
NEUTROPHIL COUNT DECREASED343 reports
HYPOAESTHESIA341 reports
HAIR DISORDER336 reports
HYPERTENSION329 reports
GENERAL PHYSICAL HEALTH DETERIORATION327 reports
MALIGNANT NEOPLASM PROGRESSION316 reports
CARDIOTOXICITY315 reports
ERYTHEMA311 reports
SEPSIS309 reports
PAIN IN EXTREMITY306 reports
HYPERSENSITIVITY298 reports
ACUTE KIDNEY INJURY297 reports
LEUKOPENIA295 reports
BONE PAIN283 reports
NASOPHARYNGITIS283 reports
CELLULITIS281 reports
CHEST DISCOMFORT279 reports
METASTASES TO BONE272 reports
ANXIETY268 reports
INSOMNIA268 reports
METASTASES TO LIVER268 reports
CHEST PAIN266 reports
SEIZURE263 reports
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME262 reports
DYSPEPSIA261 reports
BREAST CANCER259 reports
DYSGEUSIA255 reports
PNEUMONITIS255 reports
NEOPLASM PROGRESSION254 reports
INTENTIONAL PRODUCT USE ISSUE253 reports
OEDEMA PERIPHERAL251 reports
COVID 19250 reports
TACHYCARDIA248 reports
METASTASES TO LUNG242 reports
ABDOMINAL PAIN UPPER238 reports
DRY SKIN226 reports
PULMONARY EMBOLISM226 reports
LEFT VENTRICULAR DYSFUNCTION225 reports
TREMOR225 reports
MUSCLE SPASMS220 reports
ALANINE AMINOTRANSFERASE INCREASED219 reports
INFECTION215 reports
LACRIMATION INCREASED213 reports
PALPITATIONS212 reports

Report Outcomes

Out of 26,075 classified reports for PERTUZUMAB:

Serious 84.4%Non-Serious 15.6%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female21,464 (96.2%)
Male688 (3.1%)
Unknown160 (0.7%)

Reports by Age

Age 59595 reports
Age 52574 reports
Age 57553 reports
Age 55546 reports
Age 51544 reports
Age 60538 reports
Age 58520 reports
Age 54511 reports
Age 62498 reports
Age 50490 reports
Age 56487 reports
Age 65485 reports
Age 53478 reports
Age 49476 reports
Age 64427 reports
Age 61426 reports
Age 63426 reports
Age 48425 reports
Age 43416 reports
Age 42398 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with PERTUZUMAB?

This profile reflects 54,351 FDA FAERS reports that mention PERTUZUMAB. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for PERTUZUMAB?

Frequently reported terms in FAERS include DIARRHOEA, OFF LABEL USE, NAUSEA, FATIGUE, ALOPECIA, MYELOSUPPRESSION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures PERTUZUMAB?

Labeling and FAERS entries often list Genentech, Inc. in connection with PERTUZUMAB. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.